WeVote
Log In

Bill

Bill

A 3676

Establishes the Sickle Cell Treatment Act

2025 Regular Session Introduced by Rodneyse Bichotte Hermelyn and 13 co-sponsors

Establishes the Sickle Cell Treatment Act to create a statewide program for comprehensive SCD care, improve diagnosis, treatment access, and care coordination for patients.

PRINT NUMBER 3676B
0
WeVote Research Nonpartisan
Bill Summary · A 3676

Summary — A.3676 (Print 3676B): Sickle Cell Treatment Act

Status: Introduced January 29, 2025 — Print No. 3676B (amended and recommitted to Assembly Health Committee)
Primary Sponsor: Assemblywoman Alicia Hyndman
Cosponsors: Angelo Santabarbara; Brian Cunningham; Kwani O'Pharrow; Noah Burroughs; Aron Wieder; Maritza Davila; Phil Steck; Rodneyse Bichotte Hermelyn; Al Taylor; Karines Reyes; David Weprin; Larinda Hooks; Jeffrey Dinowitz

Note: The legislative text file provided to the analyst was not legible. The summary below reports known procedural facts and the bill’s stated title (“Establishes the Sickle Cell Treatment Act”), and describes typical/likely provisions and impacts based on that title. For exact statutory language, implementation details, dollar figures, or mandates, consult the official bill text on the legislature’s website (Print 3676B).

Purpose and intent

The bill’s title indicates its purpose is to establish the “Sickle Cell Treatment Act.” The general intent of such an act is to improve diagnosis, treatment, care coordination, and access to services for people living with sickle cell disease (SCD). The law would aim to reduce health disparities, improve clinical outcomes, and expand access to preventive, acute, and specialty services for SCD patients.

Key provisions (expected / typical for this type of legislation)

Because the provided bill text is unavailable, these are the types of provisions usually included in a Sickle Cell Treatment Act and are likely topics addressed by A.3676:

  • Establishes state-level standards or a program for comprehensive sickle cell care (e.g., designation or funding for SCD treatment centers or networks).
  • Requires or incentivizes care coordination between primary care, hematology specialists, emergency departments, and social services.
  • Expands screening, early diagnosis, and newborn follow-up for sickle cell disease and sickle cell trait.
  • Improves access to evidence-based treatments (e.g., hydroxyurea, chronic transfusion programs, newly approved therapies, and curative options such as bone marrow transplant or gene therapies) by addressing coverage barriers.
  • Directs the Department of Health (or another state agency) to develop clinical guidelines, provider training, and patient education.
  • Establishes data collection, reporting requirements, or a patient registry to monitor outcomes and service utilization.
  • Addresses insurance coverage and reimbursement policies (Medicaid and commercial insurers) to reduce out-of-pocket costs and prior authorization barriers.
  • May create grant programs or appropriations to support community-based services, workforce development, and patient navigation.

Who would be affected

  • Patients with sickle cell disease and their families (improved access to specialty care, treatments, and supportive services).
  • Health care providers and hospital systems (new program requirements, potential designation as SCD centers).
  • State health agencies (administration, oversight, data collection).
  • Payers including Medicaid and private insurers (coverage, reimbursement, prior authorization rules).
  • Community organizations and advocacy groups (potential grant recipients, partners in outreach).

Procedural history / timeline

  • 2025-01-29: Referred to Assembly Health Committee
  • 2025-02-05: Printed as A.3676A; amended and recommitted to Health
  • 2025-03-12: Further amendments; printed as A.3676B; amended (T) and recommitted to Health

Next steps: continued committee consideration, possible committee report and floor action in the Assembly; if enacted by the Assembly, companion Senate action would be required (S.1578 is listed as the companion). Final enactment would require concurrence in both houses and the Governor’s signature.

Related legislation

  • A.6431 (prior session)
  • A.2661 (prior session)
  • S.1578 (Senate companion)

Analyst’s recommendation

Obtain and review the official Print 3676B bill text and any committee memos or fiscal notes to confirm specific mandates, funding levels, administrative duties, effective dates, and any required appropriations. Those documents are necessary to assess fiscal impact, regulatory changes, and compliance requirements for providers and payers.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.